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Summary 
Digital PCR (dPCR) is a highly accurate method to determine DNA concentration. In dPCR 
DNA is portioned into many discrete single entities and these are analysed individually for 
the presence or absence of a target molecule of interest. Here we describe how digital PCR 
can be employed to determine the presence of oncogenic amplification through non-invasive 
analysis of circulating free DNA (cfDNA), and exemplify this approach by developing a 
plasma circulating free DNA dPCR assay for HER2 copy number. 
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1. Introduction 
Genomic amplifications are important therapeutic targets. In routine clinical practice, the 
presence of amplifications is determined by analysis of a tumor biopsy at initial diagnosis. To 
optimally deliver targeted therapy, repeated sampling of a tumor is required to determine 
whether the genetic profile of a cancer has changed following prior therapy. This would 
require repeated biopsies of recurrent and metastatic cancers, yet this approach has 
limitations. Biopsy has associated risks, may be technically challenging depending on the 
site(s) of relapsed disease, and is often costly. A biopsy usually samples only a single area of 
tumor and in heterogeneous tumors may underestimate the array of genetic aberrations 
present (1). Ideally, to overcome these limitations, and to allow repeated sampling, the 
presence of amplification could be diagnosed non-invasively. 
DNA arising from tumor cells is found in the plasma of patients with cancer and this 
represents a potential source of non-invasively analysing tumor DNA (2). High sensitivity 
assays of coding mutations on cfDNA have reported high concordance with cancer 
mutational status (3, 4)  Assays of cfDNA is non-invasive, can be repeated at multiple 
occasions throughout the disease course, and potentially may assess the full heterogeneity of 
mutations present. Analysis of cfDNA requires an assay of high sensitivity as DNA is 
frequently present at only low concentration in plasma and tumor cell derived DNA may be 
only a small fraction of the total plasma DNA (2, 5) with the remainder being derived from 
somatic cells. 
Digital PCR has the potential to highly accurately quantify the concentration of nucleic acids 
in a sample, to a much greater degree than traditional quantitative PCR, through counting 
individual DNA molecules (6).  To examine the potential of digital PCR for amplification 
detection we developed an assay to test for HER amplification on cfDNA extracted from 
plasma (7). This assay can also be used to test for HER2 amplification on formalin fixed 
paraffin embedded (FFPE) tissue and Fresh Frozen Tissue (8). Chromosomal aneuploidy 
complicates copy number assessment in plasma, and the appropriate selection of a control 
probe. Here, we employ a copy number reference gene on the same chromosomal arm as 
HER2 that is very rarely co-amplified with HER2, but is of stable neutral relative copy 
number in non-amplified cancers. 
2. Materials 
Ensure that the work is divided into clearly separated plasma processing, pre-dPCR and post-
dPCR areas and that no reagents or equipment is shared between spaces. This includes lab 
coats, reagents, plastic ware, lab books, note books, computers and any other material. 
2.1 Blood Collection, Plasma separation and Storage 
Blood should be collected into Vacutainer Plastic K2 EDTA (BD Biosciences) blood 
collection tubes as per local guidelines, separated using a horizontal rotor swing out head 
centrifuge ideally within 2 hours of processing, aliquoted into  cryogenic vials and stored at -
80
0
C. Avoid repeated thaw-freeze cycles of plasma aliquots. 
2.2 circulating free DNA (cfDNA) extraction from plasma 
Circulating free DNA (cfDNA) should be extracted from plasma using Qiagen’s QIAamp 
circulating nucleic acid kit on a dedicated plasma processing area using a QIAVac 24 Plus 
vacuum as instructed by the manufacturer. cfDNA should be eluted onto nuclease-free non-
stick 1.5-ml microcentrifuge tubes. Extracted cfDNA can be stored short term at -20
0
C. For 
long term storage consider storing cfDNA at -80
0
C. Avoid repeated thaw-freeze cycles of 
extracted cfDNA and consider aliquoting it into smaller volumes. 
2.3 Quantification and Quality control of cfDNA extracted from plasma 
cfDNA should be quantified using a fluorescence-based method like Quant-iT PicoGreen 
dsDNA assay (Thermo Fisher Scientific) or Qubit dsDNA assays (Thermo Fisher Scientific) 
on 1µl of eluate as per manufacturer instructions. Do not quantify cfDNA using a 
spectrophotometric method (260/280) as it will not be accurate enough. Alternatively cfDNA 
can be quantified using Agilent’s Bioanalyzer/Tapestation (or similar) when checking its 
quality. cfDNA quality should be checked using Agilent’s Bioanalyzer/Tapestation (or 
similar). These procedures should be carried out on dedicated pre-PCR area and equipment. 
2.4 HER2 droplet digital PCR 
Droplet digital PCR (ddPCR) should be performed on Bio-Rad’s QX100/QX200, as 
described in the methods section, on a pre-PCR area. Reactions should be performed using 2x 
ddPCR Supermix for probes (Bio-Rad). Primers and probes (Table 1) should be used at a 
final concentration of 900nM and 250nM respectively on a final volume of 20 µl (Table 2).  
3. Methods 
3.1 Venous Blood collection, Isolation of Plasma from blood and Storage 
1. Collect blood via vein puncture directly into an EDTA blood tube
1
.  




3. Remove plasma carefully without disturbing the buffy coat layer (white blood cells and 
platelets) and transfer into a clean conical centrifuge tube (Figure 1)
3
. 
4.  Centrifuge plasma at 16,000g for 10 minutes to pellet cellular debris. 
5. Pipette off all the plasma into labelled Cryogenic vials
4
. 




3.2 Circulating free DNA extraction from Plasma using a QIAvac 
Extract cfDNA from 2 ml of plasma using QIAamp circulating nucleic acid kit from Qiagen. 
Ensure that the plasma has been thaw on ice before starting procedure.  
1. Pipet 200 µl QIAGEN Proteinase K into a 50 ml centrifuge tube (not provided) 
2. Add 2 ml of plasma to the 50 ml tube. 
3. Add 1.6 ml Buffer ACL (containing 1.0 µg carrier RNA). Close the cap and mix by pulse-
vortexing for 30 sec1.  
4. Incubate at 60°C for 30 min. 
5. Place the tube back on the lab bench and unscrew the cap. 
6. Add 3.6 ml Buffer ACB to the lysate in the tube. Close the cap and mix thoroughly by 
pulse-vortexing for 15–30 sec. 
7. Incubate the lysate–Buffer ACB mixture in the tube for 5 min on ice. 
8. Insert the QIAamp Mini column into the VacConnector on the QIAvac 24 Plus. Insert a 20 
ml tube extender into the open QIAamp Mini column2.  
9. Carefully apply the lysate–Buffer ACB mixture from step 7 into the tube extender of the 
QIAamp Mini column. Switch on the vacuum pump. When all lysates have been drawn 
through the columns completely, switch off the vacuum pump and release the pressure. 
Carefully remove and discard the tube extender3.  
10. Apply 600 µl Buffer ACW1 to the QIAamp Mini column. Leave the lid of the column 
open, and switch on the vacuum pump. After all of Buffer ACW1 has been drawn through the 
QIAamp Mini column, switch off the vacuum pump and release the pressure. 
11. Apply 750 µl Buffer ACW2 to the QIAamp Mini column. Leave the lid of the column 
open, and switch on the vacuum pump. After all of Buffer ACW2 has been drawn through the 
QIAamp Mini column, switch off the vacuum pump and release the pressure. 
12. Apply 750 µl of ethanol (96–100%) to the QIAamp Mini column. Leave the lid of the 
column open, and switch on the vacuum pump. After all of ethanol has been drawn through 
the spin column, switch off the vacuum pump and release the pressure. 
13. Close the lid of the QIAamp Mini column. Remove it from the vacuum manifold, and 
discard the VacConnector. Place the QIAamp Mini column in a clean 2 ml collection tube, 
and centrifuge at full speed (20,000 x g; 14,000 rpm) for 3 min. 
14. Place the QIAamp Mini Column into a new 2 ml collection tube. Open the lid, and 
incubate the assembly at 56°C for 10 min to dry the membrane completely. 
15. Place the QIAamp Mini column in a clean 1.5 ml elution tube (provided) and discard the 
2 ml collection tube from step 14. Carefully apply 25 µl of Buffer AVE to the centre of the 
QIAamp Mini membrane. Close the lid and incubate at room temperature for 3 min4. 
16. Centrifuge in a microcentrifuge at full speed (20,000 x g; 14,000 rpm) for 1 min to elute 
the nucleic acids. 
17. Repeat steps 15 and 16 again eluting into the same tube. Final volume ~ 50 µl, labelled as 
eluate #1. 
18. Repeat steps 15 and 16 (2 x 25 µl) eluting into a fresh 1.5 ml elution tube. Label as eluate 
#2 
19. Store extracted DNA at –20°C 
3.3 Quantification of extracted cfDNA 
1. Take the Qubit dsDNA Assay Kit off the freezer and equilibrate at room temperature for 
30 minutes 
2. Make the Qubit working solution by diluting the Qubit dsDNA BR reagent 1:200 in Qubit 
dsDNA BR buffer. Do not mix the working solution in a glass container. Label two tubes for 
the standards 
3. Load 190 μl of Qubit working solution into each of the labelled standard tubes 
4. Add 10 μl of each Qubit standard to the appropriate tube and mix by vortexing 2–3 
seconds. The final volume in each tube should be 200 μl 
5. Load 199 μl of Qubit working solution into individual assay tubes 
6. Add 1 μl of plasma eluate to the tubes containing Qubit working solution. The final 
volume in each tube should be 200 μl 
7. Incubate tubes at room temperature for 2 minutes. 
8. Read the standards and plasma samples on a Qubit. 2.0 Fluorometer as instructed by the 
apparatus 
9. Calculate the concentration of the plasma samples taking into account the dilution step on 
(6) 
3.4. Checking cfDNA quality using Agilent’s Bioanalyzer 
Run 1µl of eluate on a High Sensitivity DNA chip as per manufacturer instructions.  Assess 
the quality of the extracted cfDNA based on the presence of a peak at around 150-180 bp and 
the absence of a high molecular weight peaks of more than1000 bp (Figure 2, blue trace). 
Genomic DNA (gDNA) contaminated cfDNA will exhibit high molecular weight peaks of 
more than 1000 bp (Figure 2, red trace). 
3.5. droplet digital PCR (ddPCR) for HER2 amplification 
1. For each sample prepare a reaction mix as shown in Table 3 minus the DNA into nuclease-
free non-stick 1.5-ml microcentrifuge tubes  
2. Aliquot reaction mix into 0.2 ml PCR tubes, add DNA to be analysed to tube vortex and 
spin down 
3. Assemble droplet generator cartridge into cartridge holder 




5. Aliquot 70 µl of droplet generator oil (using same tip for all wells) onto bottom row 
reservoirs of droplet generator cartridge
2
.  
6. Cover cartridge with gasket making sure ends fit over plastic overhangs. Place into droplet 
generator
3
. When done, remove cartridge from generator, remove gasket and dispose and 
collect 40 µl of droplets from top row to dispense into a PCR plate (Fisher Scientific). Collect 
droplets using an 8 channel multichannel air displacement pipette by tipping pipette at 20-25
0
 
angle and slowly (up to 15 sec) collect the droplets
4
. Dispense droplets on the PCR plate by 
tipping the pipette 20-25
0
 angle and touching the wall of the plate well, slowly (up to 15sec) 
release droplets by letting them slide along the wall of the well. Dispose of cartridge
5
. 
7. Repeat as many times as needed, covering wells between droplet generations 
8. Seal Plate and run samples on Thermal cycler as shown in Table 4 
9. When PCR cycling is complete, read droplets on a QX100/QX200 Droplet Reader as per 
manufacturer instructions. Read the plate using Absolute Quantification 
10. Samples that do not have at least 400 WT droplets should be bulk up by running more 
sample until at least 400 WT droplets are analysed 
3.6. droplet digital PCR (ddPCR) Analysis 
Data produced on the QX100/QX200 reader may be analysed using Bio-Rad Quantasoft 
software. Gate the 4 distinct populations produced by the assay as shown in Figure 3 and use 
the in-built analysis tool to calculate the ratio of HER2 to EFTUD2 reference assay. Values 
above ratio of 1.25 should be considered amplified, while ratios below that should be 
considered non-amplified. 
For optimal results in samples, and in particular in samples with a copy number ratio near to 
the cut-off, the sequential probability ratio test (SPRT) (Figure 4A) should be used to 
determine whether the copy number is elevated, not-elevated, or indeterminate. The SPRT 
uses the maximum likelihood method to determine whether the observed ratio is above or 
below the threshold within acceptable bounds of error, or whether further digital PCR runs 
are required to determine the copy number ratio. 
For data analysis using the SPRT test with a threshold likelihood ratio of 8, as previously 
reported with modifications (9, 10) should be used. Only informative droplets should be 
analysed, i.e., those droplets positive for either HER2 alone or EFTUD2 alone. The 
proportion of informative droplets positive for the HER2 is calculated PHER2 = NHER2/N where 
NHER2 is the number of droplets positive for HER2 alone, and NEFTUD2 is the number of 
droplets positive for EFTUD2 alone, and N=(NHER2+NEFTUD2) the number of informative 
droplets. 
The boundaries of the SPRT test are calculated as follows 
Upper = ((ln 8)/N-ln d)/ln g 
Lower = ((ln1/8)/N-ln d)/ln g 
where 
d = (1-q1)/(1-q0) 
g = q1(1-q0)/q0(1-q1) 
and 
q1 = the proportion of informative droplets positive for HER2 if alternative hypothesis is 
accepted (plasma sample is from a patient with HER2 amplification).  
q0 = the proportion of informative droplets positive for HER2 if null hypothesis is accepted 
(plasma sample is from a patient without HER2 amplification). 
 
q1 is calculated from HER2/EFTUD2 copy number ratio (TAMP=1.3) for assigning a sample 
as HER2 positive sample, and varies according to MEFTUD2.  
q1 = (XAMP – XAMPnEFTUD2/n) / (XAMP + nEFTUD2/n - 2XAMPnEFTUD2/n) 
where XAMP=1-exp(-TAMPMEFTUD2) the expected proportion of informative droplets positive 
for HER2 at the threshold ratio TAMP.  
q0 is similarly calculated from HER2/EFTUD2 copy number ratio (TNONAMP=1.2) for 
assigning a sample as HER2 positive negative, and also varies according to MEFTUD2.  
q0 = (XNONAMP – XNONAMPnEFTUD2/n) / (XNONAMP + nEFTUD2/n - 2XNONAMPnEFTUD2/n), where 
XNONAMP=1-exp(-TNONAMPMEFTUD2) 
where XNONAMP=1-exp(-TNONAMPMEFTUD2) 
Using these equations for any given N, the upper and lower boundaries of the SPRT curve are 
calculated. If PHER2 is greater than the upper boundary then the test result is HER2 positive. If 
PHER2 is less than the lower boundary then the test result is HER2 negative. If PHER2 lies 
between the two boundaries, then further round(s) of digital PCR are required until a sample 
is above, or below, the boundaries.  
 
The SPRT uses a likelihood ratio of 8, which corresponds roughly to two sided 95% 
confidence for differentiating between ratios of 1.30 and 1.20 (9). With these parameters a 
sample with an actual HER2:EFTUD2 ratio of, for example, 1.15 would have a very high 
probability (>99.9%) of being correctly called as negative, and likewise a sample with an 
actual ratio of 1.35 would have a very high probability of being correctly called as positive.  
Figure 4B illustrates the use of the STR test on a cohort of 58 metastatic breast cancer 
patients (11with HER2-amplified cancers and 47 with HER2-nonamplified cancers. Red 
triangles indicate patients with HER2-amplified tumors and black triangle HER2-
nonamplified tumors. The displayed SPRT decision boundaries are for illustrative purposes 
only, as the exact level varies according to the EFTUD2 control probe concentration 
(MEFTUD2), with the displayed boundaries calculated with MEFTUD2 =0.025. Cases with a 
number of informative droplets >5,000 are not displayed (7) 
4. Notes 
4.1 Venous Blood collection, Isolation of Plasma from blood and Storage 
1. When collecting blood, haemolysis must be avoided. 
2. EDTA BCTs should be stored in an upright position at room temperature and centrifuge 
within 2 hours of sample collection. 
3. Invert the ETDA tube gently 8 to 10 times immediately prior to centrifugation. 
4. Use a piston-driven air displacement pipette (avoid using a Pasteur pipette) to remove the 
plasma. 
5. When freezing plasma do not use polystyrene boxes. 
4.2 Circulating free DNA extraction from Plasma using a QIAvac 
1. Make sure that a visible vortex forms in the tube. In order to ensure efficient lysis, it is 
essential that the sample and Buffer ACL are mixed thoroughly to yield a homogeneous 
solution Do not interrupt the procedure at this time. Proceed immediately to the lysis 
incubation step. 
2. Make sure that the tube extender is firmly inserted into the QIAamp Mini column in order 
to avoid leakage of sample. Keep the collection tube for the dry spin in step 13. 
3. Note that large sample lysate volumes may need up to 10 min to pass through the QIAamp 
Mini membrane by vacuum force. To avoid cross-contamination, be careful not to move the 
tube extenders over neighbouring QIAamp Mini Columns. 
4. Ensure that the elution buffer AVE has been warmed to 42°C before use. Elution volume is 
flexible and can be adapted according to the requirements of downstream applications. The 
recovered eluate volume will be up to 5 µl less than the elution volume applied to the 
QIAamp Mini column. 
4.3. droplet digital PCR (ddPCR) for HER2 amplification 
1. Carefully load the cartridge and do not introduce bubbles onto the bottom of the reservoirs. 
Always fill all wells on a generator cartridge. If less than 8 samples then fill empty wells with 
20 µl of 2 x Buffer Control kit. 
2. Droplet generator oil contains EtOH so do not leave tube open for very long time to avoid 
evaporation. Always add the oil after having added the sample to the central row of the 
reservoir to avoid oil filling up the micro-channels connecting the reservoirs with oil. 
3. When loading the cartridge onto the droplet generator, be careful as to not spill oil (hold by 
central part). Droplets will be generated in around 2 minutes. 
4. Collecting droplets slowly will prevent droplets from breaking up and sticking together. 
5. Once droplets are generated and deposited onto the PCR plate cover filled wells with tape 
to prevent evaporation. 
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Figure Legends 
Figure 1. When separating plasma for extraction of cfDNA, only the top layer should be 
taken. The buffy coat layer containing White Blood Cells should be left undisturbed 
 
Figure 2. cfDNA extracted from plasma free from contaminant gDNA should exhibit a peak 
at around 150-300bp when analysed on the Bioanalyzer/Tapestation (blue trace), while 







 Figure 3. Representative droplet digital plots from a sample with high level amplification 
(A), and a non-amplified sample (B). The four quadrants represent top left – droplets with 
HER2 DNA only, top right – droplets with both HER2 and EFTUD2 DNA, bottom right – 
droplets with EFTUD2 DNA only, and bottom left – droplets with no DNA. 
 Figure 4. A. Droplet Digital PCR with a FAM labeled HER2 probe and VIC labeled 
EFTUD2 probe. DNA is partitioned into droplets, and after PCR, droplets are assessed by a 
fluorescent reader. The concentration of DNA in each sample can be quantified from the 
number of wells positive using the Poisson distribution. This is further analyzed with the 
SPRT using informative droplets, those droplets positive for HER2 or EFTUD2 alone, and 
not those positive for both or neither. The SPRT assesses whether the proportion of 
informative wells positive for HER2, informative wells ratio, is elevated as data accumulates. 
SPRT defines 2 boundaries, with a ratio above the upper boundary being considered HER2-
positive and below the lower boundary considered HER2-negative. A ratio between the 2 
boundaries is considered as unassigned, and the sample is subjected to further rounds of 
digital PCR until the result is above or below the boundaries. B. Analysis of digital PCR with 
Sequential Probability Ratio Test (SPRT) using informative droplets on a cohort of 58 
metastatic breast cancer patients, 11patients with HER2-amplified cancers and 47 patients 
with HER2-nonamplified cancers. Red triangles indicate patients with HER2-amplified 
tumors and black triangle HER2-nonamplified tumors. Adapted from H. Gevensleben et al., 
Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clinical cancer 
research : an official journal of the American Association for Cancer Research 19, 3276-
3284 (2013) with permission from The American Association of Cancer Research (AACR) 
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 Table 2. Final concentration of primers and probe son the HER2 amplifictaion assay. 
 
Table 3. PCR master mix components and volume used for HER2 amplification testinmg on 
cfDNA. 
 
Table 4. PCR conditions for HER2 amplification testing on cfDNA extractetd from plasma. 
